Loading...
•
Mar 31, 2024
Scholar Rock Q1 2024 Earnings Report
Scholar Rock reported financial results and corporate updates
Key Takeaways
Scholar Rock reported no revenue for Q1 2024. Net loss was $56.9 million, or $0.59 per share. The company's cash, cash equivalents, and marketable securities totaled $238 million as of March 31, 2024, expected to fund operations into the second half of 2025. Topline data from the Phase 3 SAPPHIRE trial is expected in 4Q 2024.
On track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy in 4Q 2024
Initiating Phase 2 proof-of-concept trial evaluating apitegromab in obesity in June 2024
Updated SRK-181 clinical data selected for oral presentation at ASCO
New SRK-439 preclinical data selected for oral presentation at ADA
Forward Guidance
Scholar Rock is preparing for the pivotal Phase 3 readout of apitegromab in SMA and continuing to progress their cardiometabolic program. The company's cash position enables them to reach multiple upcoming key milestones as they prepare for their next phase of growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...